TINAVI Medical Technologies (688277) Fundamentals 2026 — Revenue Analysis | SniperIQ
TINAVI Medical Technologies (688277) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥8.9B, trading at ¥19.09 on the SHH. This SniperIQ fundamentals page covers TINAVI Medical Technologies's valuation, profitability (net margin -79.6%), revenue (¥279M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is TINAVI Medical Technologies's market cap?
TINAVI Medical Technologies (688277) has a market capitalization of approximately ¥8.9B, trading at ¥19.09 on the SHH. Market cap moves with the live share price.
What is TINAVI Medical Technologies's P/E ratio?
TINAVI Medical Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is TINAVI Medical Technologies?
TINAVI Medical Technologies runs a net profit margin of -79.6%, a gross margin of 66.2%, and an operating margin of -66.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does TINAVI Medical Technologies generate?
TINAVI Medical Technologies reported revenue of ¥279M for fiscal year 2025, with net income of -¥183M and earnings per share (EPS) of -0.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does TINAVI Medical Technologies pay a dividend?
TINAVI Medical Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is TINAVI Medical Technologies financially healthy?
TINAVI Medical Technologies carries a debt-to-equity ratio of 0.16x and a current ratio of 2.83x, with a market beta of 0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is TINAVI Medical Technologies a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TINAVI Medical Technologies (688277) the key facts are: market cap ¥8.9B, revenue ¥279M, 52-week range 14.14-29.05. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track TINAVI Medical Technologies's full fundamentals live
Get TINAVI Medical Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.